Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine

scientific article published on 23 September 2016

Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1080/08039488.2016.1230649
P698PubMed publication ID27658459

P50authorOlli KampmanQ40680939
Mari HämäläinenQ42291296
Esa LeinonenQ114130753
Merja L ViikkiQ114130758
Niko SeppäläQ114130791
P2093author name stringEeva Moilanen
Jari-Pekka Klemettilä
P2860cites workA Systematic Review of Mortality in SchizophreniaQ22253025
Human resistin in cardiovascular diseaseQ27025765
Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effectsQ28657600
Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathwaysQ33762512
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).Q34018491
Adipose tissue, inflammation and atherosclerosisQ34096337
Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetesQ34765830
Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional studyQ34944648
Adipokine resistin predicts anti-inflammatory effect of glucocorticoids in asthmaQ35052648
Association of circulating resistin with metabolic risk factors in Indian females having metabolic syndromeQ35245193
Soluble urokinase-type plasminogen activator receptor levels in patients with schizophreniaQ35369617
Factors associated with inflammation markers, a cross-sectional analysisQ35633792
Sexual differences in the control of energy homeostasisQ35896671
Inhibition of mouse brown adipocyte differentiation by second-generation antipsychoticsQ36301864
Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysisQ36621075
The cytokine network in asthma and chronic obstructive pulmonary diseaseQ36955575
Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohortsQ37067145
Resistin, adiponectin, and risk of heart failure the Framingham offspring studyQ37178491
Effects of tobacco smoke on immunity, inflammation and autoimmunityQ37665006
COPD and the metabolic syndrome: an intriguing association.Q37941499
The adipocyte as an endocrine organ in the regulation of metabolic homeostasisQ37971439
Functional and structural features of adipokine familyQ38047622
Dietary pattern analysis and biomarkers of low-grade inflammation: a systematic literature reviewQ38122431
Adipokines as drug targets in joint and bone disease.Q38125858
The social and economic burden of treatment-resistant schizophrenia: a systematic literature reviewQ38133371
Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysisQ38398066
Mortality and causes of death in schizophrenia in Stockholm county, SwedenQ38495726
Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis.Q38545272
Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophreniaQ41734144
Plasma resistin levels are associated with insulin resistance in older Japanese men from a rural villageQ44537213
Cytokine and adipokine alterations in patients with schizophrenia treated with clozapineQ45372399
Adipocytokine resistin correlates with oxidative stress and myocardial injury in patients undergoing cardiac surgeryQ45817748
Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression.Q45906631
Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychoticsQ46416824
Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophreniaQ46564715
Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis.Q46568292
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatmentQ46595376
Smoking and weight among patients using clozapineQ47173896
The expression of human resistin in different leucocyte lineages is modulated by LPS and TNFalphaQ47790914
Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia.Q50619277
Smoking associates with visceral fat accumulation especially in women.Q50711325
Resistin is linked to inflammation, and leptin to metabolic syndrome, in women with inflammatory arthritis.Q51483437
The association of resistin with coronary disease in the general population.Q54647001
Resistin Is an Indicator of the Metabolic Syndrome According to Five Different Definitions in the Finnish Health 2000 SurveyQ57417417
P433issue2
P921main subjectschizophreniaQ41112
P304page(s)89-95
P577publication date2016-09-23
P1433published inNordic Journal of PsychiatryQ15751569
P1476titleResistin as an inflammatory marker in patients with schizophrenia treated with clozapine
P478volume71

Reverse relations

cites work (P2860)
Q58712660C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review
Q47612632C-reactive protein levels and treatment resistance in schizophrenia-A Danish population-based cohort study
Q94561344Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics
Q90365072Monocyte count in schizophrenia and related disorders: a systematic review and meta-analysis

Search more.